Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Copyright © 2014 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 155(2014), 2 vom: 04. Dez., Seite 160-75
1. Verfasser: Wang, Yao (VerfasserIn)
Weitere Verfasser: Zhang, Wen-ying, Han, Qing-wang, Liu, Yang, Dai, Han-ren, Guo, Ye-lei, Bo, Jian, Fan, Hui, Zhang, Yan, Zhang, Ya-jing, Chen, Mei-xia, Feng, Kai-chao, Wang, Quan-shun, Fu, Xiao-bing, Han, Wei-dong
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Anti-CD20 chimeric antigen receptor (CAR) T cells; Delayed toxicities Diffuse large B-cell lymphoma (DLBCL); Refractory advanced; Antigens, CD20 Receptors, Antigen, T-Cell Recombinant Fusion Proteins Tumor Necrosis Factor Receptor Superfamily, Member 9